Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neos Therapeutics, Inc.NEOS · Entity 141061 | Chief Executive Officer | March 01, 2018 | March 05, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neos Therapeutics, Inc.
Report date March 01, 2018 · Filed March 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,748 |
Reported balance
After 2018-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-03-01 · Grant · Acquired 25,000 · Balance 160,748 F1: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2028-03-01 | Direct | 75,000 |
Reported balance
After 2018-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-01 · Grant · Acquired 75,000 · Balance 75,000 F2: This stock option will vest in four equal, annual installments beginning on March 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest in four equal, annual installments beginning on March 1, 2019.
F2: This stock option will vest in four equal, annual installments beginning on March 1, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Altimmune, Inc.
Report date January 30, 2026 · Filed February 02, 2026
Section 16 reporting ended · disclosed 2026-02-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 424,519 |
Ending reported balance
After 2026-01-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-30 · Exercise / conversion · Acquired 26,775 · Balance 429,225 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Row 2 · 2026-01-30 · Tax withholding · Disposed 11,632 · Balance 417,593 F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Row 3 · 2026-01-31 · Grant · Acquired 6,926 · Balance 424,519 F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026 F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,775 |
Reported balance
After 2026-01-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-30 · Exercise / conversion · Disposed 26,775 · Balance 26,775 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026
F4: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025
F5: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2022 Filed Sep 1, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 20,000 | $20.02 | $400,322.00 |
DisclosureSEC source: 0001104659-22-097013 · tm2224977-1_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,797 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.19, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $18.94 | $56,952.58 |
DisclosureSEC source: 0001104659-22-097013 · tm2224977-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,797 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| August 12, 2022 Filed Aug 12, 2022 23:55 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 15,000 | $15.06 | $225,889.50 |
DisclosureSEC source: 0001104659-22-090288 · tm2223405-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,804 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2022 Filed Aug 1, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $12.01 | $36,114.07 |
DisclosureSEC source: 0001104659-22-084791 · tm2222306-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,804 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:17 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $11.70 | $35,181.90 |
DisclosureSEC source: 0001104659-22-076849 · tm2220259-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,811 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| May 30, 2022 Filed May 31, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,008 | $5.03 | $15,130.24 |
DisclosureSEC source: 0001104659-22-066739 · tm2217376-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,818 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| April 30, 2022 Filed May 2, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,008 | $4.52 | $13,596.16 |
DisclosureSEC source: 0001104659-22-054853 · tm2214195-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,826 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $6.05 | $18,192.35 |
DisclosureSEC source: 0001104659-22-041223 · tm2211105-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,834 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 00:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $7.41 | $22,281.87 |
DisclosureSEC source: 0001104659-22-028856 · tm228070d1_4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,841 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 75,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · derivative · entry 6 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,800 Underlying: Common Stock, par value $0.0001 · 75,800 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 223,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · derivative · entry 5 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,000 Underlying: Common Stock, par value $0.0001 · 223,000 shares Expires 2032-02-02 F6 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · derivative · entry 4 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,636 Underlying: Common Stock, par value $0.0001 · 16,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 7,655 | $7.98 | $61,086.90 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · nonDerivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,848 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · nonDerivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2022 Filed Feb 4, 2022 00:56 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 2,757 | $6.86 | $18,913.02 |
DisclosureSEC source: 0001104659-22-011518 · tm225504-2_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,958 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022. Read SEC document |
| January 30, 2022 Filed Feb 1, 2022 00:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,355 | $7.20 | $16,956.00 |
DisclosureSEC source: 0001104659-22-009882 · tm224965-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,201 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $8.93 | $26,852.51 |
DisclosureSEC source: 0001104659-22-000547 · tm2136680d1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,556 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $10.49 | $31,543.43 |
DisclosureSEC source: 0001104659-21-145580 · tm2134377-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,563 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| October 30, 2021 Filed Nov 1, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $10.80 | $32,475.60 |
DisclosureSEC source: 0001104659-21-132479 · tm2131531d1_4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,570 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $11.31 | $34,009.17 |
DisclosureSEC source: 0001104659-21-122159 · tm2128463d8_4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,577 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,008 | $14.09 | $42,382.72 |
DisclosureSEC source: 0001104659-21-111727 · tm2126724d1_4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,584 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $9.07 | $27,273.49 |
DisclosureSEC source: 0001104659-21-099032 · tm2123845-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,592 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,007 | $9.85 | $29,618.95 |
DisclosureSEC source: 0001104659-21-088398 · tm2121286d1_4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,599 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| May 30, 2021 Filed Jun 2, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,577 | $12.65 | $32,599.05 |
DisclosureSEC source: 0001104659-21-075895 · tm2118163-1_4seq1.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,606 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| April 30, 2021 Filed May 4, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,999 | $14.47 | $28,925.53 |
DisclosureSEC source: 0000899243-21-018238 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,183 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,998 | $13.55 | $27,072.90 |
DisclosureSEC source: 0000899243-21-014273 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,182 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,998 | $15.94 | $31,848.12 |
DisclosureSEC source: 0000899243-21-008692 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,180 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 66,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004754 · doc4.xml · derivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,181 Underlying: Common Stock, par value $0.0001 · 66,181 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 241,500 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0000899243-21-004754 · doc4.xml · derivative · entry 2 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,500 Underlying: Common Stock, par value $0.0001 · 241,500 shares Expires 2031-02-01 F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2022 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 31, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,055 | $12.14 | $12,807.70 |
DisclosureSEC source: 0000899243-21-004754 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,178 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2020 through January 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2021. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,353 | $14.28 | $33,600.84 |
DisclosureSEC source: 0000899243-21-003893 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,123 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 3,025 | $11.30 | $34,182.50 |
DisclosureSEC source: 0000899243-21-000118 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,476 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| November 30, 2020 Filed Dec 3, 2020 00:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,243 | $12.23 | $27,431.89 |
DisclosureSEC source: 0000899243-20-032574 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,501 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $11.45 | $23,071.75 |
DisclosureSEC source: 0000899243-20-030113 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,744 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $13.20 | $26,598.00 |
DisclosureSEC source: 0000899243-20-026921 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,759 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| August 30, 2020 Filed Aug 31, 2020 22:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $17.62 | $35,504.30 |
DisclosureSEC source: 0000899243-20-023683 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,774 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 22:40 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 11,674 | $1.46 | $17,044.04 |
DisclosureSEC source: 0000899243-20-021205 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,789 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2020 through July 31, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 1, 2020. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 22:06 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $26.06 | $52,510.90 |
DisclosureSEC source: 0000899243-20-021020 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,115 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 22:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $10.71 | $21,580.65 |
DisclosureSEC source: 0000899243-20-018161 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,130 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| May 30, 2020 Filed Jun 2, 2020 23:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $9.28 | $18,699.20 |
DisclosureSEC source: 0000899243-20-014937 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,145 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| April 30, 2020 Filed May 4, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $3.05 | $6,145.75 |
DisclosureSEC source: 0000899243-20-011911 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,160 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,016 | $3.02 | $6,088.32 |
DisclosureSEC source: 0000899243-20-009897 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,175 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 23:01 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $3.70 | $7,455.50 |
DisclosureSEC source: 0000899243-20-006772 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,191 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 01:24 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 11,289 | $1.46 | $16,481.94 |
DisclosureSEC source: 0000899243-20-002986 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,206 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2019 through January 31, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2020. Read SEC document |
| January 30, 2020 Filed Feb 4, 2020 00:36 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,015 | $1.77 | $3,566.55 |
DisclosureSEC source: 0000899243-20-002630 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,917 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:02 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 149,500 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-20-000279 · doc4.xml · derivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,500 Underlying: Common Stock, par value $0.0001 · 149,500 shares Expires 2030-01-02 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,999 | $1.80 | $3,598.20 |
DisclosureSEC source: 0000899243-20-000074 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,932 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| November 30, 2019 Filed Dec 4, 2019 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 23,976 | $1.82 | $43,636.32 |
DisclosureSEC source: 0000899243-19-028409 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,931 F1 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock. Read SEC document |
| September 05, 2019 Filed Sep 5, 2019 21:04 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 20,000 | $2.10 | $42,000.00 |
DisclosureSEC source: 0000899243-19-022846 · doc4.xml · nonDerivative · entry 1 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,907 Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:08 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 111,421 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001012975-18-001273 · edgar.xml · derivative · entry 3 Garg Vipin K · CIK 0001515813 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,421 Underlying: Common Stock, par value $0.0001 · 111,421 shares Expires 2028-11-30 F4 · derivative.exercise_date: One-fourth of the shares underlying the stock option will vest on the one-year anniversary of the grant date and thereafter 1/48th of the shares underlying the stock option will vest monthly commencing on January 1, 2020, such that the shares underlying the stock option will be fully vested on December 1, 2022, generally subject to Dr. Garg's continued employment with Altimmune on the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.